The Human Whole Genome siRNA Set V1.0 — a powerful discovery tool
28 Jan 2006: QIAGEN has introduced an exciting new product to its range of solutions for high-throughput RNAi — the Human Whole Genome siRNA Set V1.0.
QIAGEN
|
The Human Validated Kinase siRNA Set
 28 Jan 2006: QIAGEN has announced the development of the first-ever functionally tested set of siRNAs targeting human kinase genes.
QIAGEN
|
Sigma-Aldrich Expands shRNA Libraries of the RNAi Consortium
23 Jan 2006: Sigma-Aldrich (Nasdaq: SIAL), a leading Life Science and High Technology company, proudly announces the newest release of the MISSION™ TRC shRNA human and mouse libraries for RNA interference (RNAi)-based research.
Sigma-Aldrich Corporation
|
Cellomics rallies the largest gathering of high content screening and analysis expertise at annual User Group meeting and RNAi tutorial
17 Jan 2006: As the leader and founder of High Content Screening (HCS), Cellomics, Inc. is pleased to be the executive sponsor of the Cambridge Healthtech Institute (CHI) annual High Content Analysis (HCA) and RNAi for Pathway Analysis conferences to be held in San Francisco, February 1-3.
Thermo Fisher Scientific
|
QIAGEN develops leading solutions for RNA interference in the world’s largest siRNA validation project
13 Dec 2005: QIAGEN have announced the development of the world’s largest collection of validated siRNAs through an extensive validation project.
QIAGEN
|
Sigma-Aldrich Strengthens Position in RNAi Through Licensing and Equity Positions in Benitec and Oxford BioMedica
28 Oct 2005: Sigma-Aldrich, (Nasdaq: SIAL) a leading $1.4 billion Life Science company announced today that it has signed a series of agreements that expand its position in the area of RNA Interference (RNAi).
Sigma-Aldrich Corporation
|
Benitec Grants Sigma-Aldrich License to RNAi Patent Portfolio
25 Oct 2005: Benitec Ltd. (ASX: BLT), a leading developer of RNA interference (RNAi)-based therapeutics, and Sigma-Aldrich Corporation (Nasdaq: SIAL), a leading supplier of biochemical reagents and kits used in life sciences research, announced today the signing of two major agreements, one in which Sigma acquires an equity stake in Benitec and one in which Benitec grants Sigma a license for the use of Benitec's RNAi technology.
Sigma-Aldrich Corporation
|
The Human Druggable Genome siRNA Set — a powerful tool for drug discovery using RNAi
 11 Oct 2005: QIAGEN announces today delivery of its new Human Druggable Genome siRNA Set V2.0 to the Scripps Research Institute in Florida. This second generation siRNA set from QIAGEN enables gene silencing studies of 6992 potential human druggable targets. siRNAs are designed using the innovative HiPerformance siRNA Design Algorithm, ensuring maximum silencing and minimum risk of nonspecific effects.
QIAGEN
|
QIAGEN collaborates with Institut Curie to develop high-throughput RNAi tools
10 Oct 2005: QIAGEN and Institut Curie announced today a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project. This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.
QIAGEN
|
Sigma-Aldrich Expands The MISSION™ RNAi Product Line
09 Aug 2005: The RNAi Consortium (TRC) shRNA Libraries grow to include new gene targets
Sigma-Aldrich Corporation
|
